A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Joaquı́n Mateo(Vall d'Hebron Institute of Oncology), Debyani Chakravarty(Memorial Sloan Kettering Cancer Center), Rodrigo Dienstmann(Vall d'Hebron Institute of Oncology), S. Jezdic(European Society for Medical Oncology), Abel González-Pérez(Institute for Research in Biomedicine), Núria López-Bigas(Institució Catalana de Recerca i Estudis Avançats), Charlotte K.Y. Ng(University Hospital of Basel), Philippe L. Bédard(Princess Margaret Cancer Centre), Giampaolo Tortora(University of Verona), J.-Y. Douillard(European Society for Medical Oncology), Eliezer M. Van Allen(Broad Institute), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Charles Swanton(The Francis Crick Institute), F. André(Institut Gustave Roussy), Lajos Pusztai(Yale Cancer Center)
Cited by 777Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis